Fechter et al. selected a novel aptamer to target integrin α5β1-expressing cells, and applied it to distinguish glioblastoma cell lines and tissues from patient-derived tumor xenografts according to their α5 expression levels [58]. This evidence concerns the gene IGKV2D-26 and neoplasm.